ValiRx PLC Publication of Peer-Reviewed Articles on VAL401
February 28 2017 - 1:02AM
RNS Non-Regulatory
TIDMVAL
ValiRx PLC
28 February 2017
ValiRx Plc
('ValiRx' or the 'Company')
PEER-REVIEWED PUBLISHED ARTICLES SUPPORTING VALIRX &
VALISEEK'S ANTI-CANCER TECHNOLOGY
London, UK, 28 February 2017: ValiRx Plc (AIM: VAL), a clinical
stage biotechnology company, announces the recent publication of
two articles in peer-reviewed journals that examine drug
reprofiling in oncology and the progress of novel cancer treatment
drug, VAL401, in its Clinical Efficacy trials for the treatment of
lung cancer and other oncology indications.
Publications
The first article is titled "A Chemical Genomics Approach to
Drug Reprofiling in Oncology: Antipsychotic Drug Risperidone as a
Potential Adenocarcinoma Treatment". Accepted for publication in
Cancer Letters, Volume 393, 2017, Pages 16-21 and co-authored by Dr
Suzy Dilly, Professor Paul Taylor, University of Leeds, alongside
other academic staff at both the University of Warwick and Leeds
University, this peer-reviewed communication details the
experimental processes that led to the formulation of the VAL401
process.
The second publication is Bentham Science and is titled "Pimping
up Drugs Recovered, Superannuated and Under Exploited Drugs - An
Introduction to the Basics of Drug Reprofiling", Current Drug
Discovery Technologies, 2017, 14, 000-000, by Dr George Morris, COO
of ValiRx plc and Dr Suzy Dilly, CEO of ValiSeek. They explore
examples of success in reprofiling, draw comparisons between
techniques, and finally provide two examples from the ValiRx plc
development pipeline currently undergoing the process.
A third article appears as an advertising feature in the March
2017 issue of "BioPharma Dealmakers" (a Nature publication)
describing the licensing opportunity of VAL401 as an oncology
treatment and summarises the expectations of the current trial.
Future Conferences
Dr Victoria D'Aquino, Research and Development Officer at
ValiRx, submitted an abstract on the current VAL201 clinical trial,
which has been accepted for poster presentation at the 15(th)
International Congress on Targeted Anti-Cancer Therapies ("TAT") in
Paris, France, on 6-8 March 2017.
Dr Suzy Dilly will attend the Bio-Europe Spring bio-partnering
conference on 20-22 March 2017, in Barcelona, Spain. This
conference represents a further opportunity to continue to develop
conversations with potential partners and licensees.
About ValiRx
ValiRx is a biotechnology oncology focused company specialising
in developing novel treatments for cancer and associated
biomarkers. It aims to make a significant contribution in
"precision" medicine and science, namely to engineer a breakthrough
into human health and well-being, through the early detection of
cancer and its therapeutic intervention.
The Company's business model focuses on out-licensing
therapeutic candidates early in the development process. By aiming
for early-stage value creation, the company reduces risk
considerably while increasing the potential for realising value.
The group is already in licensing discussions with major players in
the oncology field.
ValiRx's two classes of drugs in development, which each have
the potential for meeting hitherto unmet medical needs by existing
methods, have worldwide patent filings and agreed commercial
rights. They originate or derive from Word class institutions, such
as Cancer Research UK and Imperial College.
Until recently, cancer treatments relied on non-specific agents,
such as chemotherapy. With the development of target-based agents,
primed to attack cancer cells only, less toxic and more effective
treatments are now possible. New drugs in this group-such as those
in ValiRx's pipeline-promise to greatly improve outcomes for cancer
patients.
The Company listed on the AIM Market of the London Stock
Exchange in October 2006 and trades under the ticker symbol:
VAL.
About ValiSeek
ValiSeek Limited ("ValiSeek") is a joint venture ("JV") company
between ValiRx Plc and Tangent Reprofiling Limited, part of the
SEEK Group. ValiSeek was formed to progress the drug VAL401 through
its remaining preclinical development and towards Phase II trials
for the treatment of lung cancer and other oncology
indications.
For more information, please contact:
ValiRx plc Tel: +44 (0) 20 3008
4416
www.valirx.com
Dr Satu Vainikka, Chief Executive Tel: +44 (0) 20 3008
4416
Tarquin Edwards, Head of Communications. Tel: +44 (0) 7879
458 364
tarquin.edwards@valirx.com
Mark Treharne, Corporate Development Tel: +44 (0) 7736
Manager 564 686
mark.treharne@valirx.com
*** ENDS ***
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRADMGZZVNMGNZM
(END) Dow Jones Newswires
February 28, 2017 02:02 ET (07:02 GMT)
Valirx (LSE:VAL)
Historical Stock Chart
From Apr 2024 to May 2024
Valirx (LSE:VAL)
Historical Stock Chart
From May 2023 to May 2024